title: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study.
abstract: BACKGROUND
  We sought to evaluate prognostic factors affecting overall survival (OS), and to investigate the role of palliative chemotherapy using propensity score-based weighting, in patients with advanced small bowel adenocarcinoma (SBA).
  
  
  METHODS
  Data from a total of 91 patients diagnosed with advanced SBA at the Asan Medical Center between January 1989 and December 2009 were retrospectively analyzed. Patients were split into two groups, those who did and did not receive palliative chemotherapy.
  
  
  RESULTS
  Overall, 81 patients (89.0%) died, at a median survival time of 6.6 months (95% confidence interval [CI], 5.5 - 7.5 months). The 40 patients receiving chemotherapy showed overall response and disease control rates of 11.1% and 37.0%, respectively, with OS and progression-free survival (PFS) of 11.8 months (95% CI, 4.6 - 19.0 months) and 5.7 months (95% CI, 3.5 - 8.0 months), respectively. The 41 patients who did not receive chemotherapy had an OS of 4.1 months (95% CI, 3.1 - 5.1 months) and a PFS of 1.3 months (95% CI, 0.8 - 1.7 months). Multivariate analysis showed that lack of tumor resection, non-prescription of chemotherapy, liver metastasis, and intra-abdominal lymph node metastasis, were all independently associated with poor survival outcomes. After inverse probability of treatment weighting (IPTW) adjustment, the group that did not receive chemotherapy was at a significantly higher risk of mortality (HR 3.44, 95% CI 2.03 - 5.83, p < 0.001) than were patients receiving chemotherapy.
  
  
  CONCLUSIONS
  Palliative chemotherapy may improve survival outcomes in patients with advanced SBA.
authors: Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
authors: Dong Hoe
authors: DH
authors: Koo
authors: Sung-Cheol
authors: SC
authors: Yun
authors: Yong Sang
authors: YS
authors: Hong
authors: Min-Hee
authors: MH
authors: Ryu
authors: Jae-Lyun
authors: JL
authors: Lee
authors: Heung-Moon
authors: HM
authors: Chang
authors: Baek-Yeol
authors: BY
authors: Ryoo
authors: Yoon-Koo
authors: YK
authors: Kang
authors: Tae Won
authors: TW
authors: Kim
references: Ann Oncol. 2010 Sep;21(9):1786-1793
references: 20223786
references: Cancer. 2008 Oct 15;113(8):2038-45
references: 18759326
references: Oncologist. 2005 Feb;10(2):132-7
references: 15709215
references: Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9
references: 17355111
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Am J Clin Oncol. 2006 Jun;29(3):225-31
references: 16755174
references: Jpn J Clin Oncol. 2009 Jan;39(1):54-61
references: 18997182
references: Gastric Cancer. 2008;11(4):201-5
references: 19132481
references: Epidemiology. 2000 Sep;11(5):550-60
references: 10955408
references: J Clin Oncol. 2009 Jun 1;27(16):2598-603
references: 19164203
references: Gastrointest Cancer Res. 2009 May;3(3):90-6
references: 19626152
references: Cancer. 2004 Aug 1;101(3):518-26
references: 15274064
references: Surg Today. 2009;39(1):27-31
references: 19132464
references: Stat Med. 1998 Oct 15;17(19):2265-81
references: 9802183
references: Cancer Causes Control. 2005 Sep;16(7):781-7
references: 16132788
references: J Cancer Res Clin Oncol. 2010 Mar;136(3):387-94
references: 19760196
references: Oncology. 2005;69(4):290-4
references: 16282708
references: Br J Cancer. 1998 Aug;78(4):508-10
references: 9716035